Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.6% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 33,013 shares of the biopharmaceutical company’s stock after purchasing an additional 2,880 shares during the period. Oddo BHF Asset Management Sas’ holdings in Alnylam Pharmaceuticals were worth $10,923,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. iA Global Asset Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after acquiring an additional 16,133 shares during the period. Perpetual Ltd acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $2,004,000. Hussman Strategic Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $2,505,000. GF Fund Management CO. LTD. boosted its position in Alnylam Pharmaceuticals by 989.1% during the fourth quarter. GF Fund Management CO. LTD. now owns 30,462 shares of the biopharmaceutical company’s stock worth $12,113,000 after purchasing an additional 27,665 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its position in Alnylam Pharmaceuticals by 22.6% during the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after purchasing an additional 16,503 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Bank of America dropped their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Citigroup began coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective on the stock. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the company an “equal weight” rating in a report on Friday, July 10th. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $452.13.

Alnylam Pharmaceuticals Stock Down 0.6%

ALNY opened at $286.62 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The stock has a market capitalization of $38.27 billion, a price-to-earnings ratio of 78.31 and a beta of 0.27. The business has a 50-day moving average of $291.70 and a two-hundred day moving average of $313.42. Alnylam Pharmaceuticals, Inc. has a 12 month low of $262.21 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the firm posted ($0.44) EPS. The company’s revenue was up 96.4% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.35 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.